Hepacivirus

Study on 169 patients (87males, 82 females) aged from 21 to 71 years old in order to determine, quantify as well as type hepatitis C virus. Immunoassay was used to detect anti HCV and serotype of HCV from patients’ sera; molecular biology assay was used to detect HCV-RNA (using RT-PCR target the 5’UT region of viral genome), and to quantify the HCV in the patients’ blood (using bDNA). Results: the rate positive HCV-RNA were 70% among 319 cases with anti HCV (+). In 169 cases that have been done serotype tests, the most common serotypes were type 6 (44.38%), followed by type 1 (37.28%). Type 1 is referred as the most difficult to response to the specific treatment. The results of quantitative assay showed that type 1 and type 6 infected patients had high quantity of viremia. From this study, the roles of the molecular biology assays were defined as the very necessary in diagnosis as well as treatment of patients with HCV infection
Hepacivirus ; Diagnosis

The relative distribution of hepatitis C virus (HCV) genotypes was determined for 123 blood donors. Genotyping was performed using a commercial reverse phase hybridization assay after amplification of the 5’ untranslated region of HCV by the polymerase chain reaction. The isolates comprised, genotype 1a (15.4%), genotype 1b (48.8%), genotype 1 (5.6%), genotype 2 (0.8%), genotype 2a/2c (8%), genotype 4 (0.8%), genotype 6a (14.6%), unusual genotype pattern (2.4%). And serotype hepatitis C virus from genotype 1b was determined
Hepacivirus ; Genotype

Genotypes of hepatitis C virus are clinically relevant to epidemiology, prognosis and therapeutical management of HCV infection. Our study aims to compare different methods for HCV genotyping. Hepatitis C genotypes and subtypes of infected patients in Ho Chi Minh city was determined by serological typing using HCV serotyping 1-6 (Murex company), by molecular typing using Innolipa HCV II assay (Innogenetics NY) and direct sequencing of core and NS5b region. Our results show that the hepatitis C virus by analysing the sequences of the core and NS5b regions gave concordant results. The NS5b region is reliable for the identification of HCV subtype 6 circulating in Viet Nam.
Hepacivirus ; Viruses

Background: Co-infection by human immunodeficiency and hepatitis C viruses (HIV/HCV) is common and results in significant morbidity and mortality despite effective antiretroviral therapies (ART). Method: A retrospective and prospective evaluation of the efficacy and safety of pegylated interferon alfa 2a/2b plus ribavirin (PEG-IFN/RBV) in consecutive HIV/HCV co-infected patients treated in real life clinical practice in Malaysia. Results: Forty-five HIV/HCV co-infected patients with a median age (interquartile range, IQR) of 41 years (37; 47) were assessed for treatment with PEG-IFN/RBV. All except one are of male gender and the most common risk behaviour was injecting drug use. At baseline 75.5% was on ART and the median (IQR) CD4 count was 492 cells/µl (376; 621). The HCV genotypes (GT) were 73 % GT3 and 27% GT1. Liver biopsies in forty patients showed 10% had liver cirrhosis and another 50% had significant liver fibrosis. The treatment completion rate was 79.5% with 15.9% dropped out of treatment due to adverse effects (AE) or default and 4.6% due to lack of early virological response. The AE causing premature discontinuations were neuropsychiatric and haematological. The overall sustained virological response (SVR) was 63.6% with a trend towards higher SVR in GT3 compared with GT1 (71.9% vs. 41.7%; p=0.064). In patients with bridging fibrosis plus occasional nodules or cirrhosis on liver biopsy, the SVR was significantly lower at 20% (p=0.030) compared to those with milder fibrosis. Conclusion: HIV/HCV co-infected patients can be successfully and safely treated with PEG-IFN/RBV achieving high rates of SVR except in cirrhotic patients.
HIV ; Hepacivirus

No abstract available.
Hepacivirus* ; Hepatitis C* ; Hepatitis*

Hepacivirus ; Hepatitis C ; Humans

No abstract available.
Hepacivirus* ; Hepatitis C* ; Hepatitis*

No abstract available.
Hepacivirus* ; Hepatitis C* ; Hepatitis*

No Abstract Available.
Hepacivirus* ; Hepatitis C* ; Hepatitis*